Search alternatives:
values increased » cases increased (Expand Search), also increased (Expand Search), rate increased (Expand Search)
larger decrease » marked decrease (Expand Search)
i values » _ values (Expand Search)
c larger » _ larger (Expand Search), c large (Expand Search), _ large (Expand Search)
a large » _ large (Expand Search)
values increased » cases increased (Expand Search), also increased (Expand Search), rate increased (Expand Search)
larger decrease » marked decrease (Expand Search)
i values » _ values (Expand Search)
c larger » _ larger (Expand Search), c large (Expand Search), _ large (Expand Search)
a large » _ large (Expand Search)
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
Dehydration-Rehydration Studies on Polytypes of Chloride and Nitrate Layered Double Hydroxides of Nordstrandite and Bayerite: a Comparative Study
Published 2022“…Dehydration of nitrate intercalated LDH, which proceeds from an orthorhombic symmetry to a monoclinic symmetry with no decrease in the interlayer spacing, is attributed to sliding of the hydroxyl layers in the <i>ab</i>-plane due to the increase in the β value. …”
-
151
Dehydration-Rehydration Studies on Polytypes of Chloride and Nitrate Layered Double Hydroxides of Nordstrandite and Bayerite: a Comparative Study
Published 2022“…Dehydration of nitrate intercalated LDH, which proceeds from an orthorhombic symmetry to a monoclinic symmetry with no decrease in the interlayer spacing, is attributed to sliding of the hydroxyl layers in the <i>ab</i>-plane due to the increase in the β value. …”
-
152
-
153
-
154
-
155
-
156
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
157
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
158
-
159
-
160